Although SLC19A3 deficiency is considered to be a treatable entity, the literature review showed that sixty percent of previously reported patients with either BTBGD or a Leigh phenotype had poor outcomes, including early death, tetraparesis, dystonia or cognitive impairment. Here, SLC19A3 is linked to Tetraparesis.